 | Up a level |
Horn, Michael P; Jonsdottir, Hulda R; Brigger, Daniel; Damonti, Lauro; Suter-Riniker, Franziska; Endrich, Olga; Froehlich, Tanja K; Fiedler, Martin; Largiadèr, Carlo R; Marschall, Jonas; Weber, Benjamin; Eggel, Alexander; Nagler, Michael (2022). Serological testing for SARS-CoV-2 antibodies in clinical practice: a comparative diagnostic accuracy study. Allergy, 77(7), pp. 2090-2103. Wiley 10.1111/all.15206
Brigger, D.; Horn, M. P.; Pennington, L. F.; Powell, A. E.; Siegrist, D.; Weber, B.; Engler, O.; Piezzi, V.; Damonti, L.; Iseli, P.; Hauser, C.; Froehlich, T. K.; Villiger, P. M.; Bachmann, Martin F.; Leib, S. L.; Bittel, P.; Fiedler, M.; Largiadèr, C.; Marschall, J.; Stalder, H.; ... (2021). Accuracy of serological testing for SARS-CoV-2 antibodies: first results of a large mixed-method evaluation study. Allergy, 76(3), pp. 853-865. Wiley 10.1111/all.14608
Schaerer, Dominic; Froehlich, Tanja K.; Hamzic, Seid; Offer, Steven M.; Diasio, Robert B.; Joerger, Markus; Amstutz, Ursula; Largiadèr, Carlo R. (2020). A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. Journal of personalized medicine, 10(4) MDPI 10.3390/jpm10040181
Hamzic, Seid; Kummer, Dominic; Froehlich, Tanja K.; Joerger, Markus; Aebi, Stefan; Palles, Claire; Thomlinson, Ian; Meulendijks, Didier; Schellens, Jan H M; García-González, Xandra; López-Fernández, Luis A; Amstutz, Ursula; Largiadèr, Carlo R. (2020). Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacological research, 152, p. 104594. Elsevier 10.1016/j.phrs.2019.104594
Hamzic, Seid; Wenger, N; Fröhlich, Tanja; Joerger, M; Aebi, Stefan; Largiadèr, Carlo Rodolfo; Amstutz, Ursula (2017). The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics journal, 17(4), pp. 319-324. Nature Publishing Group 10.1038/tpj.2016.23
Meulendijks, D; Henricks, LM; Amstutz, Ursula; Fröhlich, Tanja; Largiadèr, Carlo Rodolfo; Beijnen, JH; de Boer, A; Deenen, MJ; Cats, A; Schellens, JHM (2016). Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International journal of cancer, 138(11), pp. 2752-2761. Wiley-Blackwell 10.1002/ijc.30014
Kummer, Dominic; Fröhlich, Tanja; Joerger, Markus; Aebi, Stefan; Sistonen, Johanna; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2015). Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics, 16(12), pp. 1367-1377. Future Medicine 10.2217/pgs.15.81
Fröhlich, Tanja; Amstutz, Ursula; Aebi, Stefan; Joerger, Markus; Largiadèr, Carlo Rodolfo (2015). Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. International journal of cancer, 136(3), pp. 730-739. Wiley-Blackwell 10.1002/ijc.29025
Sistonen, Johanna; Büchel, Barbara; Fröhlich, Tanja; Kummer, Dominic; Fontana, Stefano; Joerger, Markus; van Kuilenburg, André B P; Largiadèr, Carlo Rodolfo (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics, 15(13), pp. 1653-1666. Future Medicine 10.2217/pgs.14.126
Mueller, F; Büchel, B; Köberle, D; Schürch, Stefan; Pfister, B; Krähenbühl, St; Fröhlich, Tanja; Largiader, C R; Joerger, M (2013). Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology, 71(2), pp. 361-70. Berlin: Springer 10.1007/s00280-012-2018-4
Amstutz, Ursula; Froehlich, Tanja K; Largiadèr, Carlo R (2011). Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics, 12(9), pp. 1321-36. London: Future Medicine 10.2217/PGS.11.72
